Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism (2017)

Peer-Reviewed Study · Karagiannis GS, Pastoriza JM, Wang Y, et al.; Condeelis JS, Oktay MH (senior) · July 5, 2017

Karagiannis GS et al., 2017-07-05: Mouse-model and patient-tissue study showing paclitaxel-based neoadjuvant chemotherapy increases TMEM (tumor microenvironment of metastasis) density and Mena isoform expression and promotes distant metastasis in models; in patient samples TMEM score rose after chemotherapy even as tumours shrank.

in the residual breast cancers of patients treated with neoadjuvant paclitaxel after doxorubicin plus cyclophosphamide, TMEM score and its mechanistically connected MENAINV isoform expression pattern were both increased, suggesting that chemotherapy, despite decreasing tumor size, increases the risk of metastatic dissemination.

p.eaan0026 (Abstract)

Karagiannis GS et al., 2017-07-05: Mouse-model and patient-tissue study showing paclitaxel-based neoadjuvant chemotherapy increases TMEM (tumor microenvironment of metastasis) density and Mena isoform expression and promotes distant metastasis in models; in patient samples TMEM score rose after chemotherapy even as tumours shrank. Competing interests (verbatim): 'J.S.C. and M.H.O. are inventors on a patent application (#96700/2505) submitted by Albert Einstein College of Medicine that covers methods of detecting and reducing chemotherapy-induced prometastatic changes in breast tumors.' Funding not stated in the abstract. No drug maker: paclitaxel and doxorubicin/cyclophosphamide are generic. Comparator: pre- versus post-treatment tissue in the same patients, plus vehicle-treated murine controls – not a randomised clinical comparison. An erratum exists (Sci Transl Med 2017;9(399):eaao3817). Study type: animal.